Investor Relations
Investor News
| October 1, 2025 | Timely Disclosure Information | StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Psoriasis |
|---|---|---|
| September 26, 2025 | Timely Disclosure Information | StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator |
| September 18, 2025 | Timely Disclosure Information | StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators |
| September 16, 2025 | IR News | Presentation Materials Financial Results for the Fiscal Year Ended July 31 2025 |
INFORMATION
Stock Information
LIBRARY
Investor Library
CALENDAR
COVERAGE
| Firm | Analyst |
|---|---|
| Nomura Securities Co., Ltd. | Mr. Maeda Kouta |
| Nomura Securities Co., Ltd. | Mr. Hiroyuki Matsubara |
| Marusan Securities Co., Ltd. | Mr. Tsuyoshi Ono |
- This list of analysts was prepared based on material that was available at the time of writing. Therefore, please note that there may be other analysts who have not been included in this list, and that some of the information may not be the latest.
- Please note that the analysts have conducted their own analyses of the Company’s performance, businesses, products and technologies, and have developed their own forecasts. These processes do not in any way involve the Company or the management of the Company.
- Furthermore, the management of StemRIM does not endorse or concur with the forecasts, opinions and recommendations of these analysts. Thus, we cannot take any responsibility regarding the consistency of such information.
- The provision of this list is explicitly for the purpose of introducing analysts of external companies or research-related institutions that have undertaken analyses and forecasts of our corporate performance. This is not for the purpose of soliciting sales of the Company’s stock.
- Please note that decisions regarding the purchase of shares are solely up to the investors themselves.